Public Health Fact Sheet
Involving the Community in Responding to TB/HIV: Outcomes of Community-Led Monitoring and Advocacy
Accessed November 2017
Key populations brief
Accessed November 2017
Working Document, September 2017
Annex 1: Measuring progress towards targets
Annex 2: Modelling the impact of the 90-(90)-90 strategy
Annex 3: Investment packages by country setting
Annex 4: Country strategies
Annex 5: Strategic frameworks for research and development for new tools
Annex 6 : Estimating the cost of the 90-(90)-...90 strategy
Accessed November 2017
more
The tuberculosis survival project .. your cure, your life
Accessed November 2017
Key populations brief
Accessed 2017
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
An analysis from the perspective of the health sector in Latin America and the Caribbean
Washington, D.C., 2017
PQDx 0027-012-00 WHO
PQDx Public Report
May/2017, version 4.0
3rd Edition – July 2017
www.msfaccess.org
L’OMS a ciblé 17 maladies comme des Maladies Tropicales Négligées. Ces maladies sont très différentes les unes des autres, mais elles ont comme point commun de toucher principalement les populations les plus pauvres. Elles maintiennent dans la pauvreté les populations ayant initialement un n...iveau de développement faible. Ces maladies coexistent au sein des mêmes populations, augmentant de ce fait leur vulnérabilité.
more
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
Technical Update
HIV Treatment
July 2017
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
These guidelines present evidence-based recommendations and best practice statements on use of medically important antimicrobials in food-producing animals, based on the WHO list of critically important antimicrobials for human medicine (WHO CIA List). These guidelines aim primarily to help preserve... the effectiveness of medically important antimicrobials, particularly those antimicrobials judged to be critically important to human medicine and also help preserve the effectiveness of antimicrobials for veterinary medicine, in direct support of the WHO global action plan on antimicrobial resistance
more
5th revised edition.
This document provides a ranking of medically important antimicrobials for risk management of antimicrobial resistance due to non-human use. The current revision took place at the seventh meeting of the AGISAR held in Raleigh, United States of America in 2016.